EGFR and non-small cell lung carcinoma: This phenomenon might help explain the subpar effectiveness observed in EGFR-mutant NSCLC patients, regardless of whether they are administered with direct PD-L1/PD-1 inhibitors or have transitioned to these immunotherapies after developing TKI resistance.